Your current location is set to United States. If this is incorrect, please change your location:
We respect and honour your right to make decisions for the benefit of your own health. The MS Society recently shared preliminary unpublished findings from the Canadian CCSVI trial which aimed to determine whether the CCSVI procedure would alleviate MS-related symptoms. These preliminary results suggest that the CCSVI procedure is ineffective in treating MS.
Having a Conversation with Your Doctor about CCSVI Testing or Procedures
The primary concern of physicians is safe-guarding your health, including ensuring that any treatments you take are safe (or have well-understood risks), potentially effective and ethical. If after a discussion, you decide to go for a CCSVI procedure, keep your doctor(s) informed of this decision.
CCSVI is a hypothetical condition that might be diagnosed in a
variety of ways. One is through high resolution imaging
technologies to view (or "image") the primary veins that carry
blood from the central nervous system (brain and spinal cord)
to the heart. This imaging is used to detect either one or both
of what are considered key indicators of CCSVI:
You can read more about diagnostic approaches on the CCSVI Alliance website
CCSVI-related procedure centres can be found throughout the
world. If you are seeking to have a procedure done, explore all
possibilities in North America prior to considering options
overseas. Venous angioplasty is not major surgery but it is
invasive. Complications can occur and they can be serious.
Follow-up procedures are sometimes called for. If any follow-up
care is needed, you are in a much better position if you have
rapid access to your medical team and are able to communicate
in your own language.
Ask the centre:
You can read more about centres that offer the procedure here
Venous Dilation
Stents
Some people have stents inserted into their veins. Stents are made for use in arteries, not veins. The risks increase with the use of stents. Stents can migrate (move out of place), and there is an increased chance of blood clotting when a stent used. The reports of serious complications are especially common in those who were treated with stents. Dr. Zamboni's initial research did not involve the use of stents and he advises against their use. If you do get a stent, be sure to get all of the information you can about the stent that has been used so that your physicians at home know what material it is made of and whether or not it is MRI compatible.
There is higher risk when stents are used.
We understand that thousands of individuals worldwide have had a CCSVI-related procedure performed. The reports from individuals range widely. Some people report that they were tested but no blockages were found in their veins. Others describe little or no change in MS symptoms. Many others report moderate or even dramatic improvement in symptoms.
According to Dr. Zamboni's initial studies, the treatment was of benefit for relapsing rather than progressive forms of MS. 47% of those in Dr. Zamboni's study re-stenosed (had blockages in their veins again) within 18 months of the procedure.
Preliminary unpublished results from the Canadian CCSVI trial confirmed that treating vein narrowing is ineffective in treating MS.
DMTs underwent rigorous trials prior to being approved and are shown to reduce relapse rates from 33% to 68%, depending on the treatment. They are also shown to slow the progression of disability in the disease. It is highly inadvisable that you cease your current treatment without recommendation from your neurologist or physician.
Combining DMTs with the CCSVI procedures does not appear to add any additional risk, though again, more information from studies and trials, if warranted, will provide more information.
The cost of CCSVI-related procedures varies depending on the centre. Most seem to offer the procedure for approximately $5000-$9,000 USD. You may also need to consider the cost associated with travel, accommodation, need for vaccinations etc.
While some information regarding risks and safety has been gathered, more is needed. Gathering definitive risk and safety information with respect to CCSVI-related diagnosis and procedures is complicated by the lack of standardized methodology or equipment in the testing and procedures currently being done. While there may be information on safety with respect to interventions in the arteries, we do not have much information with respect to veins and the venous system. We do know, however, that the risks are not insignificant. Prospective candidates should know that there have been reports of CCSVI surgical procedures resulting in adverse events, including deaths. According to the Annals of Neurology, a person died of a hemorrhage in the brain while taking a blood thinner (anti-coagulant), which is commonly prescribed when stents are inserted into blood vessels. In another instance, a Canadian man died from complications during follow-up surgery after having a stent inserted in Costa Rica.
Short-Term and Long-Term RisksWhen people look at the risks of the procedure, they often consider only the immediate or short-term risks. These include some relatively rare risks:
There are however, other risks that are not immediately apparent:
If you are concerned that you might have complications resulting from a CCSVI-related procedure, be sure to seek immediate medical help. The first step in making the diagnosis of a blood clot is obtaining a history. Be sure to share all information you have regarding your recent procedure. Venous blood clots often develop gradually, over hours, with swelling, pain, and discoloration of the affected area. An extremity (e.g, arm or leg) may swell and be red, warm and tender.
If the clot has dislodged and moved to the lungs (pulmonary embolism), the symptoms will involve shortness of breath and pain. This is very serious and potentially life-threatening. If there is concern about a blood clot in the lungs (pulmonary embolus), your physician may first listen to the lungs looking for abnormal sounds caused by an area of inflamed lung tissue.